MedTrace Logo

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

NCT06416410 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2025-04-04

No results posted yet for this study

Summary

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

DRUG

JAB-21822

JAB-21822 administered orally as a tablet

DRUG

Tislelizumab

Tislelizumab administered as an intravenous (IV) infusion

DRUG

JAB-3312

JAB-3312 administered orally as a tablet or capsule

DRUG

Pemetrexed

Pemetrexed administered as an intravenous (IV) infusion

DRUG

Carboplatin

Carboplatin administered as an intravenous (IV) infusion

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Wang Jie M.D. · Cancer Institute and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-07
Primary Completion
2026-09-30
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06416410 on ClinicalTrials.gov